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SUMMARY
BACKGROUND: Compared with smear microscopy, Xpert® MTB/RIF has the potential to 
reduce delays in tuberculosis (TB) diagnosis and treatment initiation, and improve treatment 
outcomes. We reviewed publications comparing treatment outcomes of drug-susceptible TB 
patients diagnosed using Xpert vs. smear.
METHODS: Citations (2000–2016) reporting treatment outcomes of patients diagnosed using 
Xpert compared with smear were selected from PubMed, Scopus and conference abstracts. We 
conducted a systematic review and meta-analysis. Favorable (cured, completed) and unfavorable 
(failure, death, loss to follow-up) outcomes were pooled for meta-analysis; we also reviewed the 
number of TB cases diagnosed, time to treatment and empiric treatment. The Mantel-Haenszel 
method with a fixed-effect model was used; I2 was calculated to measure heterogeneity.
RESULTS: From 13 citations, 43 594 TB patients were included and 4825 were with known TB 
treatment outcome. From the pooled analysis, an unfavorable outcomes among those diagnosed 
using Xpert compared with smear was 20.2%, 541/2675 vs. 21.9%, 470/2150 (risk ratio 0.92, 
95%CI 0.82–1.02). Statistical heterogeneity was low (I2 = 0.0%, P = 0.910). Compared with 
smear, Xpert was reported to be superior in increasing the number of TB patients diagnosed (2/9 
citations), increasing bacteriologically confirmed TB (7/9 citations), reducing empiric treatment 
(3/5 citations), reducing time to diagnosis (2/3 citations), and reducing time to treatment initiation 
(1/5 citations).
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CONCLUSIONS: Xpert implementation showed no discernible impact on treatment outcomes 
compared with conventional smear despite reduced time to diagnosis, time to treatment or reduced 
level of empiric treatment. Further research is required to learn more about gaps in the existing 
health system.
RÉSUMÉ
Comparé à la microscopie de frottis, l’Xpert® MTB/RIF a le potentiel de réduire les délais de 
diagnostic et de mise en route du traitement de la tuberculose (TB) et d’améliorer les résultats du 
traitement. Nous avons revu les publications comparant les résultats du traitement des patients 
atteints de TB pharmacosensible diagnostiquée par Xpert contre frottis.
Les références (2000–2016) rapportant les résultats du traitement des patients, diagnostiqués par 
Xpert comparé au frottis, ont été sélectionnés sur PubMed, Scopus et dans des résumés de 
conférence. Nous avons conduit une revue systématique et une méta-analyse. Les résultats 
favorables (guéri, traitement achevé) et défavorables (échec, décès, perdus de vue) ont été 
regroupés pour une méta-analyse; nous avons revu les nombres de cas de TB diagnostiqués, le 
retard de traitement et la proportion de traitement empirique. Nous avons utilisé la méthode de 
Mantel-Haenszel avec un modèle à effet fixe ; I2 a été calculé afin de mesurer l’hétérogénéité.
A partir de 13 références, 43 594 patients TB ont été inclus et le résultat du traitement de TB a été 
connu pour 4825 d’entre eux. Selon l’analyse regroupée, les résultats défavorables parmi les 
patients diagnostiqués par Xpert comparés au frottis ont été de 20,2%, 541/2675 contre 21,9%, 
470/2150 (ratio de risque de 0,92; IC95% 0,82–1,02). L’hétérogénéité statistique a été faible (I2 = 
0,0%; P = 0,910). Comparé au frottis, l’Xpert s’est avéré supérieur en augmentant le nombre de 
patients TB diagnostiqués (2/9 références), en accroissant les TB confirmées par bactériologie (7/9 
références), en réduisant le traitement empirique (3/5 références), en réduisant le retard de 
diagnostic (2/3 références) et en réduisant le retard de mise en route du traitement (1/5 références).
La mise en œuvre de l’Xpert n’a pas misen évidence d’impact discernable sur les résultats du 
traitement comparé au frottis conventionnel, en dépit d’une diminution du délai de diagnostic, du 
délai de traitement ou de la réduction du traitement empirique. Il faut davantage de recherche pour 
en savoir plus sur les lacunes du système de santé existant.
RESUMEN
En comparación con la baciloscopia del esputo, la prueba Xpert® MTB/RIF puede disminuir el 
retraso del diagnóstico de la tuberculosis (TB) y del inicio del tratamiento y mejorar los desenlaces 
terapéuticos. Se llevó a cabo una revision de las publicaciones que comparaban los desenlaces 
terapéuticos de pacientes con TB normosensible diagnosticada por la prueba Xpert y de los 
pacientes diagnosticados mediante baciloscopia.
Se buscaron referencias de estudios que comparaban los desenlaces terapéuticos de pacientes 
diagnosticados mediante la prueba Xpert y la baciloscopia en las bases de datos de PubMed, 
Scopus y en resùmenes de conferencias (2000–2016). Se llevó a cabo una revisión sistemática y 
un metanálisis. Con fines del metanálisis se combinaron los desenlaces favorables (curados, 
tratamiento completo) y desfavorables (fracaso, muerte y pérdida durante el seguimiento); se 
analizó el nûmero de casos de TB diagnosticados, el lapso hasta el inicio del tratamiento y la 
prescripción de un tratamiento empírico. Se aplicó el método de Mantel-Haenszel con un modelo 
de efectos fijos y se midió la heterogeneidad mediante el estadístico I2.
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En las 13 citas encontradas, se incluían 43 594 pacientes con TB y en 4825 casos se conocía el 
desenlace del tratamiento antituberculoso. Segùn el análisis combinado, la proporción de 
desenlaces desfavorables en los pacientes diagnosticados con la prueba Xpert fue 20,2% 
(541/2675), comparada con 21,9% (470/2150) en los pacientes diagnosticados por baciloscopia 
(cociente de riesgos 0,92; IC95% 0,82–1,02). La heterogeneidad estadística fue baja (I2= 0,0%; P 
= 0,910). Los estudios comunicaban que, comparada con la baciloscopia, la prueba Xpert era 
superior para aumentar el nùmero de pacientes diagnosticados (2/9 citas), aumentar los casos de 
TB confirmados bacteriológicamente (7/9 citas), disminuir el tratamiento empírico (3/5 citas), 
acortar el lapso hasta el diagnóstico (2/3 citas) y para acortar el tiempo hasta el inicio del 
tratamiento (1/5 citas).
La utilización de la prueba Xpert no reveló un impacto perceptible sobre el desenlace terapéutico, 
en comparación con la baciloscopia corriente, pese al acortamiento del tiempo hasta obtener el 
diagnóstico y el lapso hasta el inicio del tratamiento y a la disminución de los tratamientos 
empiricos. Las investigaciones futuras deberán aportar nuevas aclaraciones sobre las lagunas que 
existen en el sistema de salud vigente.
Keywords
patient-level; treatment outcome; Xpert; smear
TUBERCULOSIS (TB) TREATMENT outcomes remain a concern among clinicians, 
particularly among TB patients co-infected with the human immunodeficiency virus (HIV), 
who have a high risk of mortality (~40%), even when receiving antiretroviral therapy (ART).
1
 Less sensitive, traditional TB diagnostic methods such as smear microscopy contribute to 
poor treatment outcomes; a missed diagnosis of TB can lead to late patient presentation and 
delayed TB treatment initiation.2,3 Smear has low sensitivity (~45 %) in diagnosing culture-
positive disease among people living with HIV (PLHIV).4,5
The Xpert® MTB/RIF assay is a real-time, fully automated molecular test developed on the 
GeneXpert platform (Cepheid, Sunnyvale, CA, USA), which can detect both 
Mycobacterium tuberculosis complex (MTC) and rifampicin (RIF) resistance within 2 h.6,7 
After endorsement by the World Health Organization (WHO) in 2010, over 145 countries 
had implemented the assay, as of December 2016.8
Recent evidence from meta-analysis suggests that in comparison with smear, Xpert shows a 
23% increase in TB detection among culture-confirmed cases.9 Studies have indicated that 
Xpert has superior sensitivity (79–88%) than smear for TB diagnosis.9–11 In addition to 
diagnosing more TB cases, the shorter turnaround time of diagnosis using Xpert has the 
potential to reduce delays in TB treatment initiation and improve patient-level clinical 
outcomes.12 Since 2013, the WHO has been recommending the use of Xpert rather than 
conventional microscopy as the initial diagnostic test in all adults; however, we have yet to 
see an improvement in treatment outcomes, including mortality and morbidity.9 There is 
limited published evidence with detailed patient-level clinical outcomes on the impact of 
Xpert compared with smear.
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From the limited emerging evidence comparing the use of Xpert vs. smear, varying results 
have been reported on the impact of Xpert on patient-level clinical outcomes. The majority 
of the reports agree that the inability to show improved clinical impact (treatment outcome) 
of Xpert over smear is potentially a result of a high level of empiric anti-tuberculosis 
treatment. The expectation is not that clinicians can eliminate use of empiric treatment, 
particularly in childhood TB and in smear-negative TB; however, compared with smear, 
Xpert has higher sensitivity to accurately diagnose TB and higher specificity to identify true-
negatives, and this may be beneficial to patients, who would be spared unnecessary anti-
tuberculosis treatment.13–17 Patients with non-tuberculous mycobacteria (NTM) disease who 
present with symptoms similar to TB are particularly at risk of avoidable empiric anti-
tuberculosis treatment. Patients with NTM who receive anti-tuberculosis treatment may have 
unfavorable outcomes because NTMs do not respond, or partially respond (depending on the 
NTM species), to anti-tuberculosis treatment.18 We conducted a systematic review and meta-
analysis to establish the effect of Xpert on treatment outcomes.
The aims of the present review were primarily to compare smear and Xpert assays among 
TB patients to determine if Xpert reduces: 1) unfavorable outcomes (failure, death, loss to 
follow-up [LTFU]); 2) time to diagnosis and time to treatment; 3) use of empiric treatment.
METHODS
Search strategy
We followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA) guidelines.19 This systematic review and meta-analysis is registered at 
PROSPERO (http://www.crd.york.ac.uk/PROSPERO; number CRD42016050625).
As Xpert is a relatively new TB diagnostic technology, we searched PubMed and Scopus for 
all relevant articles published between January 2000 and December 2016. A sensitive search 
strategy was used, with Xpert as the key heading term used in combination with potentially 
relevant key factors: Xpert AND ‘tuberculosis’; or ‘impact’; or ‘effect’; or ‘treatment 
outcome’; or ‘time to diagnosis’; or ‘time to treatment’; or ‘empiric treatment’: or ‘loss to 
follow-up’; or ‘mortality’; or ‘morbidity’.
We also reviewed abstract books from the Union World Conference on Lung Health from 
2012 to 2016 for studies that may have been completed but not yet published. In addition, 
we reviewed the reference lists of the primary studies to include additional references that 
might have been missed with our primary search strategy.
Review of studies
Studies designed as cohort studies or randomized clinical trials comparing the diagnosis 
and/or treatment outcomes of TB patients diagnosed using Xpert vs. smear were potentially 
eligible to be included in the review. Citations with patient-level treatment outcomes 
(favorable or unfavorable) comparing Xpert and smear microscopy were eligible for 
inclusion in the meta-analysis. The target study population was patients of any age or sex 
who presented with TB symptoms at any health care level.
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The inclusion criteria that studies reported on were 1) treatment outcomes in drug-
susceptible TB patients, diagnosed using Xpert compared with those diagnosed using smear; 
2) the effect of Xpert on time to diagnosis, time to treatment, empiric treatment or mortality.
The exclusion criteria were 1) studies reporting on treatment outcomes for drug-resistant 
TB; and 2) studies not reporting on patient-level treatment outcomes or whose reporting was 
from modeling studies or population-level impact. Detailed descriptions of cohort selection 
as Xpert or smear groups are included as notes under each table.
Two reviewers (TA and RB) independently reviewed study titles and abstracts to determine 
eligibility. All studies that met the inclusion criteria received full-text reviews, and 
differences were resolved by consensus.
Data extraction and statistical analysis
For studies fulfilling the inclusion criteria, two independent reviewers selected eligible 
citations and compiled data on a pre-piloted Excel™ (MicroSoft, Redmond, WA, USA) 
spreadsheet. The following information was collected, if available: article author and title, 
year of publication, study setting, population (HIV-infected and/or non-infected), participant 
demographics and baseline characteristics, details of intervention and control conditions, 
study methodology, treatment outcomes, time to diagnosis, time to treatment, diagnostic test 
(smear and Xpert), incremental value (additional TB cases diagnosed) and description of 
empiric treatment practices.
Favorable TB treatment outcomes were defined as cured or completed treatment. 
Unfavorable treatment outcomes were defined as failed, death or LTFU. Empiric treatment 
was defined as initiation of treatment in the absence of a bacteriologically confirmed 
diagnosis. Diagnostic impact (reduced time to diagnosis, increased number of TB cases 
diagnoses and increased bacteriologically confirmed TB), therapeutic impacts (reduced time 
to treatment, reduced LTFU and reduced empirical treatment) and patient-level outcomes 
(improved treatment outcome, including mortality) were described based on Schumacher et 
al.’s framework.12
The data abstracted were aggregated and summarized as favorable and unfavorable 
outcomes for patients diagnosed and treated using smear- and Xpert-based algorithms. 
Pooled analysis was conducted using the Mantel-Haenszel method with a fixed-effect model 
and a forest plot created using STATA v14.0 (STATA Corporation, College Station, TX, 
USA). The statistical test, I2, was applied to measure heterogeneity. To support the results 
from the pooled analysis, a narrative analysis of articles that did not meet the criteria for 
meta-analysis was produced to identify factors potentially affecting treatment outcomes 
(time to diagnosis and time to treatment, empiric treatment and bacteriologically confirmed 
TB).
Quality assessment
While scales such as the Detsky et al. scale can be useful, many authors consider the scoring 
schemes to be imprecise, and cut-off points can be arbitrary; we therefore did not use any 
scale or scoring system.20,21 We applied a set of strict inclusion and exclusion criteria to 
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identify as many comparable studies as possible. For consistency and to ensure high quality 
of data, two authors (TA and RB) independently reviewed methods used in potentially 
eligible articles and abstracts. The included citations provided information on how patient-
level treatment outcomes were measured and reported results using risk ratio (RR), 95% 
confidence interval (CIs) or P values. Following review, any concern or uncertainty was 
resolved by consensus.
Ethics statement
Ethical approval was not required for this systematic review.
RESULTS
A total of 683 unique citations were identified, with 89 reporting on either outcome or 
impact (Figure 1). Of these, 13 citations on drug-susceptible pulmonary TB were eligible 
and were fully reviewed; respectively 43 594 patients and 4825 with known TB treatment 
outcomes were included for systematic review and meta-analysis.
The designs of analyzed citations in the present study are included in Tables 1–4. Of the 13 
citations included in this analysis, nine (including all four citations in the meta-analysis) 
reported results from randomized clinical trials (Tables 1–4).13–16,22–26 Citations reported on 
the following, comparing those diagnosed using Xpert vs. those diagnosed using smear: 1) 
patient-level treatment outcomes among TB patients were reported in 6/13 (46%) citations 
(Table 1),13–16,25,27 and among presumptive TB patients in 5/13 (31%) citations (Table 2);
13,22,23,25,26
 2) the total number of patients with a TB diagnosis was reported in 3/13 (23%) 
citations (Table 3),27–29 and in 6/13 (46%) citations which reported on TB patients 
diagnosed among presumptive TB patients (Table 4);13,22–26 3) the proportion of 
bacteriologically confirmed TB was reported in 6/13 (46%) citations among TB patients 
diagnosed (Table 3)14,15,22,27,29,30 and in 3/13 (23%) citations among presumptive TB 
patients (Table 4);13,24,28 4) the proportion of TB patients empirically treated was reported 
in 4/13 (31%) citations (Table 3)14,22,25,27 and in 1/13 (8%) citations among presumptive TB 
patients (Table 4);26 5) the proportion of LTFU among presumptive TB was reported in 2/13 
(15%) citations (Table 4);23,25 and 6) time to diagnosis was reported in 3/13 (23%) citations,
22,25,27
 and time to treatment in 5/13 (39%) citations (Table 5).13,22,24,25,27
Meta-analysis
The four citations that fulfilled the criteria for meta-analysis were from Botswana (n = 1), 
Brazil (n = 1) and South Africa (n = 2). The data from these citations are summarized in 
Tables 1 and 6.13–16 Of a combined total of 4825 TB patients, 55% (2675/4825) were 
diagnosed using Xpert and 45% (2150/ 4825) using smear, were initiated on anti-
tuberculosis treatment and had a known treatment outcome. Bivariate analysis showed 
similar treatment outcomes between TB patients diagnosed using Xpert and smear (Table 6). 
Unfavorable outcomes were reported for respectively 20.2% (541/2675) and 21.9% 
(470/2150) of patients diagnosed using Xpert and smear. The pooled analysis showed a RR 
of 0.92 (95%CI 0.82–1.02) (Figure 2). Statistical heterogeneity was low (I2 = 0.0%, P = 
0.910).
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Tuberculosis treatment outcomes
Of the 13 reviewed citations, six reported on patient-level treatment outcomes among TB 
patients, four of which had sufficient data allowing for classification as favorable or 
unfavorable; treatment outcome was similar among those diagnosed using Xpert vs. those 
diagnosed with smear. Yoon et al. and Mupfumi et al. reported on mortality among TB 
patients at 2 and 3 months with no difference between smear and Xpert groups (Table 1).
13–16,25,27
 Another five citations, reporting among presumptive TB patients, showed no 
mortality benefit at 6 months,13,22,23,25,26 or at 3 months (Table 2).22 Cox et al. 
demonstrated superiority of Xpert to smear (21.9%, 215/982 vs. 17.5%, 176/1003; RR 1.25, 
P = 0.032) on treatment success (measured as favorable outcome) among presumptive TB 
patients.13
Reviewed diagnostic and therapeutic impact: Xpert vs. smear
TB patients diagnosed—Of the three citations reporting on the total number of TB 
patients diagnosed,27–29 only Sachdeva et al. indicated increased TB diagnosis (16%) among 
Xpert compared with smear (134/100 000 vs. 116/100 000 population, RR 1.16, P < 0.001). 
Creswell et al. reported lower than expected (8.5%, non-significant) annual pulmonary TB 
notifications at 4589 in the second year of intervention (Xpert introduction) compared with 
the baseline (pre-intervention) 5123 TB notifications.29 Of the six citations that reported on 
presumptive TB patients, only Cox et al. demonstrated a higher proportion of TB diagnosed 
in the Xpert arm than in the routine arm (smear) (28%, 277/98 vs. 23%, 299/1003; RR 1.44, 
P = 0.013); all other citations showed no incremental benefit (i.e., increased TB case 
detection), including Durovni et al., who reported results per 100 000 rather than proportions 
(79.6 vs. 91.7/100 000, smear and Xpert, respectively, P = 0.115).13,22–26 Theron et al. noted 
that the effect of Xpert, compared with smear, on incremental value was demonstrated only 
within the first 3 days after sputum collection, and the benefit was no longer seen at day 14 
(41%, 303/744 vs. 39%, 292/758, P = 0.383) and thereafter at day 28 and day 56 (Table 4).26
Empiric treatment—Of the 5 citations that reported on empiric anti-tuberculosis 
treatment, 1 was among presumptive TB patients and 4 among TB patients.15,22,25–27 In 2/4 
citations reporting on TB patients, Xpert use led to reduction in empiric treatment compared 
with smear (7%, 9/125 vs. 15%, 27/178 by Yoon et al. and 17%, 4/24 vs. 56%, 9/16 by 
Calligaro et al.) (Table 3).22,27 Theron et al. showed a decrease in empiric treatment 
compared with smear among presumptive TB patients (17%, 130/744 vs. 26%, 197/758) 
(Table 4).26
Bacteriologically confirmed TB—Of the 9 citations that reported the proportion of 
bacteriologically confirmed TB, 6 were among TB patients and 3 among presumptive TB 
patients. In 7/9 (78%) citations, Xpert was superior to smear in confirming TB 
bacteriologically.13,22–27 In studies by Yoon et al. and Calligaro et al., bacteriological 
evidence was similar between Xpert and smear; all TB patients included in these two 
analyses were hospitalized patients unlike the rest of the citations (Tables 3 and 4), in which 
Xpert was shown to be superior.
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Time to diagnosis and time to treatment—Five citations reported on time to 
treatment, three of which also reported on time to diagnosis. Compared with smear, Xpert 
significantly reduced delay in diagnosis in 2 of the 3 citations that measured time to 
diagnosis,22,25,27 and reduced time to treatment in 1/5 citations (Table 5).13,22,24,25,27 One of 
the studies reporting on time to treatment (not time to diagnosis) was by Durovni et al., who 
reported that Xpert was useful in increasing the number of TB patients who initiated 
treatment early in a Brazilian setting, compared with smear (Table 4).13,24 Theron et al. 
reported the proportion of TB patients diagnosed and initiated on treatment but did not 
report the number of days to treatment initiation (Table 4); instead, they reported that Xpert 
increased the number of TB patients diagnosed and the number of patients who were 
subsequently treated in the first 3 days after sputum collection, but that there was little 
difference between Xpert and smear groups for those starting treatment at 2, 4 and 8 weeks 
after sputum collection. In this cohort, mortality at 2 and at 6 months was similar among 
patients diagnosed using Xpert and those diagnosed using smear, irrespective of time to 
treatment initiation.26 None of the citations showed that reduced time to diagnosis or 
treatment translated into an improvement in TB treatment outcome or mortality.
Loss to follow-up—Of the two citations reported on LTFU among presumptive TB 
patients,23,25 Xpert use had no effect on reducing LTFU. Comparing Xpert vs. smear, 
Mupfumi et al. reported that LTFU was 15% (32/ 214) vs. 18% (38/210), P = 0.380, and 
Churchyard et al. reported 0.99% (23/2332) vs. 1.08% (25/2324) (P value not available) 
(Table 4).
DISCUSSION
To our knowledge, this is the first systematic review and meta-analysis of the impact of 
using Xpert compared with smear on patient-level TB treatment outcomes (coded as 
favorable and unfavorable) in the diagnosis of drug-susceptible TB. Pooled results gathered 
from the four randomized trials included in the meta-analysis demonstrated similar TB 
treatment outcomes among patients diagnosed with Xpert compared with smear, suggesting 
that Xpert has not been observed to reduce unfavorable TB treatment outcomes. No previous 
meta-analysis has compared drug-susceptible TB treatment outcomes between cohorts using 
Xpert and smear. The report by Auld et al., who reviewed eight clinical trials, was the only 
one available; they concluded that Xpert showed no impact on the key patient-level 
outcomes, mortality and morbidity.31
Recent publications have demonstrated that Xpert has the potential to increase the number of 
TB cases diagnosed,9,13,28 and microbiologically confirmed TB cases, and reduce time to 
diagnosis and treatment initiation.9,13,22,24,27,28 Beohme et al. also demonstrated that shorter 
turnaround times resulted in substantially faster initiation of anti-tuberculosis treatment, 
which resulted in a significant reduction in LTFU.10 It remains unclear as to why Xpert did 
not result in a discernible impact in terms of improvement of clinical outcome despite such 
potential.
Theron et al. hypothesized that the potential benefits from Xpert are masked by high levels 
of rapid empiric treatment,17 and several reports agreed with this assumption.13,14,26 In 
Agizew et al. Page 8
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2019 November 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
contrast, Churchyard et al. reported that Xpert could minimize the proportion of patients 
receiving empiric treatment.23 Although clinicians cannot eliminate the use of empiric 
treatment, Xpert has a higher sensitivity than smear to accurately diagnose TB and a higher 
specificity to identify true-negatives, and this may be of benefit to patients, who would be 
spared unnecessary anti-tuberculosis treatment.9,18,23 Creswell et al. demonstrated an 8.5% 
reduction in empiric treatment in Nepal when Xpert was used in program settings.29 
Churchyard et al., Creswell et al. and the present review do not support the assumption that 
the effects of Xpert are being masked by clinicians continuing a high level of empiric 
treatment. Nonetheless, the concern as to why treatment outcome has not been affected by 
reduced empiric treatment prevails. The majority of the reviewed citations in the present 
analysis indicated that the use of Xpert reduced empiric treatment, but no treatment outcome 
benefits were observed. It is also worth noting that empiric treatment may have some added 
value, particularly in TB in children and people with smear-negative TB, where Xpert 
sensitivity is lower than that in patients with smear-positive or culture-positive TB. In such 
cases, empiric treatment remains important. An editorial from Lawn et al., in support of 
Theron et al.’s hypotheses, concluded that the effect and extent of empiric treatment on 
treatment outcomes warranted further evaluations in real-world settings.17,32 An 
observational prospective study (ClinicalTrials.gov Identifier: ) was started in 2016 in 
Zambia to evaluate the effect of Xpert on patient health outcomes and empiric TB treatment 
among PLHIV. The study is expected to be completed in 2018, and the results will provide 
an opportunity to examine any association between Xpert use and empiric treatment.33
In the present analysis, we reviewed the diagnostic and therapeutic impact of Xpert, and 
their effect on patient-level treatment outcomes. In the majority of the citations (7/9), 
although Xpert increased bacteriologically confirmed TB, the effect did not translate into 
increased numbers of TB cases treated or improvement in treatment outcomes.
13,15,22,24,27–29
 We are in agreement with Auld et al. that merely replacing smear with Xpert 
is not enough to see the desired effect of highly sensitive new molecular testing.31 Another 
recent report from Auld et al. seems to support this hypothesis; their study showed a 
significant 12-month mortality reduction when enhanced care (defined as intensified case 
finding with additional staff support actively tracing patients who missed clinic 
appointments) was added to routine standard of care, rather than only replacing smear with 
Xpert. Auld et al. suggested that the intensified case finding and active tracing of TB 
patients to improve retention in care by health care workers were key factors for any 
mortality benefits.34
The need for enhanced care discussed by Auld et al. is an issue of health systems 
strengthening.31 An additional area of concern, which was not included in our systematic 
review but has a potential to negatively affect Xpert test results and thus treatment initiation, 
is sputum quality. Orina et al. from Kenya and Meyer et al. from Uganda reported concerns 
with a higher than expected proportion of salivary sputum samples collected for Xpert 
testing.35,36 The Xpert diagnostic test does not function in isolation, and considering other 
health system and pre- and post-diagnostic test-related factors in the TB diagnostic cascade 
is essential.37 There are three key intervention areas that are important to address for 
successful Xpert implementation. The first is the pre-diagnostic stage. Interventions may 
include training of Xpert operators, including proficiency tests, assessment of potential 
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diagnostic delays, both patient-related (e.g., health care seeking) and health system (e.g., 
sample transport) and assessment of optimal placement of GeneXpert instruments to 
improve access to testing (high-burden areas, point-of-care peripheral clinics or even at the 
community level if GeneXpert Omni is available). The second is the diagnostic stage. 
GeneXpert instruments should be regularly maintained and should use the latest version of 
Xpert cartridges (currently G4 or Ultra). The third area is post-diagnostic stage. Attention 
should be placed on turnaround time, early treatment initiation, reduced empiric treatment, 
and reduced LTFU by actively tracking patients after treatment initiation.
While Xpert as a highly sensitive and rapid diagnostic test is appreciated in TB control 
efforts, patient-related factors, quality sputum samples and stronger health systems seem to 
matter more than the use of innovative technology alone. Population-level TB control 
success in high-income countries was achieved long before molecular testing was 
introduced, which was not necessarily due to the diagnostic technology used.38 Having said 
this, we are not by any means minimizing the need for new Xpert molecular technology, as it 
plays a very important role in the rapid diagnosis of drug-resistant TB, extra-pulmonary TB 
and childhood TB. Furthermore, the use of the Xpert Ultra assay in settings with limited 
infrastructure is promising, and should be further explored.
Our study had seven main limitations. First, of the 13 citations that reported on the impact or 
treatment outcomes, only four fulfilled the inclusion criteria for the meta-analysis. All of 
these citations were from randomized clinical trials but the covariate data on age, sex, HIV 
status and previous history of TB were insufficient to be included in the analysis. Second, 
TB treatment outcomes for meta-analysis reported by Agizew et al. and Fielding et al. were 
adjusted for clustering,15,16 whereas data from the trial reports from Cox et al. and Trajiman 
et al. were extracted and thus not adjusted for clustering.13,14 Third, studies that measured 
delays in time to diagnosis or time to treatment used inconsistent definitions. In some 
studies, delays were measured from the time of enrollment,13,25 while in others, this was 
measured from the time of sputum sample collection;26 some did not provide clear 
definitions.22,24 Fourth, no data were available on other potential factors that could influence 
patient care and outcomes, such as delays in sample transportation, efficiency of patient 
referrals, proficiency of staff in conducting diagnostic tests, and adherence of clinicians to 
standard guidelines for patient screening, diagnosis and treatment, all of which could have 
had an effect on time to diagnosis and time to treatment. Fifth, the population studied in the 
present analysis included a mix of HIV-infected and non-infected persons, with the 
exception of two citations that included only HIV-infected persons in the analysis. Due to 
their compromised immune status, HIV-infected individuals might possibly have affected 
treatment outcomes. However, the citations which included both did not report treatment 
outcomes by HIV status; it was therefore not possible to see any impact difference between 
the HIV-infected and non-infected groups. Sixth, in the present analysis, the microbiological 
status of TB patients may have affected treatment outcomes; however, none of the citations 
included reported treatment outcomes by microbiological status. Finally, although 9/13 
citations reported in this analysis were from randomized clinical trials,14–16,22–26 the relative 
effect of the study design may have affected the impact of the interventions, as highlighted 
in a review by Auld et al.31
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In conclusion, Xpert implementation showed no discernible impact on clinical outcomes 
compared with conventional smear. Despite improved time to TB diagnosis, treatment 
initiation and/or empiric treatment, patient-level outcomes for Xpert and smear were similar. 
With the available evidence, efforts towards TB control need more than just consideration of 
replacement of smear with Xpert. Further implementation research is required to better 
understand the gaps in existing health systems. Although improved clinical outcomes have 
not yet been observed with Xpert, identifying areas of intervention for health system 
reinforcement is a worthwhile exercise on an ongoing basis. Within a wider context, 
optimizing the use of Xpert to maximize benefits, such as early diagnosis and management 
of drug-resistant TB, and diagnosis of extra-pulmonary TB and pediatric TB, are also 
essential.
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Figure 1. 
Flow chart of citations included for review and meta-analysis.
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Figure 2. 
Forest plots of unfavorable treatment outcomes among tuberculosis patients diagnosed using 
Xpert vs. smear. RR = risk ratio; CI = confidence interval.
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